Time To Tip the Scales? Humira Biosimilars And The Limitations Of Competition In US Health Care

 
• By Sarah Karlin-Smith and Jinghong Chen
  
road that splits in two directions with one direction leading toward "generic brand" and one direction leading toward "name brand"
Incentives in the US health care system make it hard for biosimilars to make inroads on brands used in the outpatient setting • Source: Shutterstock
Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

SpotifyApple PodcastsWebsite

More from Biosimilars

More from Biosimilars & Generics